Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.10.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Operating Costs and Expenses:    
General and administrative $ 5,727 $ 7,467
Research and development 11,844 18,784
Total Operating Costs and Expenses 17,571 26,251
Loss from Operations (17,571) (26,251)
Other Income:    
Change in fair value of warrant liability 4,083 10,738
Interest income 67 21
Total Other Income 4,150 10,759
Net Loss (13,421) (15,492)
Net Loss Attributable to Non-controlling Interest (54) (318)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (13,367) (15,174)
Preferred Stock Dividends (243) (73)
Net Loss Attributable to Common Stockholders $ (25,291) $ (22,136)
Net Loss Per Share - Basic and Dilutive $ (4.06) $ (6.23)
Weighted average number of shares outstanding during the period - Basic and Dilutive 6,232,442 3,553,316
Series A Preferred Stock [Member]    
Other Income:    
Preferred Stock Dividends $ (243) $ (6,962)
Series B Preferred Stock [Member]    
Other Income:    
Net Loss Attributable to Non-controlling Interest 0 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0
Preferred Stock Dividends $ (11,681) $ 0